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Clinical cases MIR: Long survivors in oncology
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Background. Substantial changes have been seen in cancer mortality rates over the past two decades, speciﬁcally breast cancer
which is the leading cause of new cancer diagnosis, it’s average decline in death rates over 2% per year since 1990, which is the
combined result of earlier diagnosis and better treatment. A cancer survivor by theNational Cancer Institute’s ofﬁcial deﬁnition is
any patient who has been diagnosed with cancer. A long-term cancer survivor is someone who has lived past the risk of primary
cancer recurrence or who has a long-term chronic malignancy. Case presentation: We describe a 61 year-old female patient who
was diagnosed in 1994 with Stage IIB (pT2pN1M0) inﬁltrating ductal carcinoma of the left breast; she was treated on February of
1994 with breast conserving therapy (lumpectomy and surgical axillary staging+QT (adriamicina+CMF×8c) +RDT). In February
of 1997 she presented bone metastases with clinical presentation of clavicle fracture. After that she was treated with multiple
chemotherapies andpalliative radiotherapy schemes (seven times ondifferent anatomical localizations) due to bone, biochemical
and visceral progression; in January of 2012 she presented osteonecrosis in left jaw due to long-term bisphosphonates. Currently
she has a karnofsky performance status of 80%, and is being treated with docetaxel with excellent response.
Conclusion. There is constant progress in breast cancer treatment, so it’s expected that in the upcoming decade it should lead to
continued decreases inmortality rates, increasing the cancer survivorship and the clinical challenges that entails. The knowledge
of the needs of long-term cancer survivors is critical to delivery of ongoing care that maximizes the beneﬁts of treatment,
minimizing and properly managing late toxicities and enhancing their quality of life.
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A 57-year-old man with 5 different squamous cell carcinoma
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Ninety percent of Head and neck cancer (H&NC) are squamous cell carcinoma (SCC). The use of tobacco is associated with an
increased risk of H&NC. Due to improvements in therapy and therefore the consequent increase in overall survival in patients
with H&NC, it is not uncommon to develop secondary neoplasms (particularly if toxic habits continue) such as other primary
H&HC, esophageal cancer (SCC is associated with tobacco, alcohol, or prior history of Head and Neck cancers) or lung cancers
(caused by carcinogens and tumor promoters inhaled via cigarette smoking) We report a 57 year-old-man with alcoholic habit of
6 drink units daily (previously 9–10) and former smoker of two packs a day (currently 10 cigarettes/day) with glomerulonephritis
secondary to leukocytoclastic vasculitis whose cancer history includes: SCC of the oropharynx T2N0 treated in June 2007 by
uvulopalatoplasty and bilateral neck dissection. Currently free of disease. SCC of tongue in 2009 treated by partial glossectomy
and right posterior cordectomy. Currently free of disease. Diagnosed in June 2011 of a synchronous SCC of the right pyriform sinus,
esophageal inﬁltrating SCC and lung adenocarcinoma, T3N1M0 and T1N0M0 respectively. Pyriform sinus tumor and esophageal
carcinoma were both treated with concurrent chemoradiation (CBDCA+5-FU-RDT plus 70Gy 2Gy/fr) with complete response by
PET/CT and EUS respectively. Lung lesion was treated by SBRT 60Gy in 8 fractions at 7.5Gy/fr. PET/CT in October 2012 objectived
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